Indeed, transcriptional fluctuations rather than acquired mutations have recently been identified to underlie drug resistance in melanoma cells [76] and chromatin regulators have been demonstrated to function not only in melanoma development but also specifically in the emergence of resistance to BRAF inhibitors ([77] and reviewed in [48]). This evidence concerns the gene BRAF and melanoma.